ALLOX Raises $10.5 Million for AI Drug Discovery Platform

Oct 29, 2026
ALLOX raised $10.5 million in seed funding to expand its drug discovery platform and advance its small molecule research programs.

ALLOX raised $10.5 million in seed funding to expand its drug discovery platform and advance internal research programs, according to Tech.eu. Asabys Partners led the round through its Sabadell Asabys II fund, with participation from CDTI through SICC Innvierte and the Institut Català de Finances.

The platform combines high throughput genetics, experimental biology and AI to find sites within proteins that could support small molecule treatments. It measures thousands of genetic mutations in parallel to identify regions that affect protein folding and interactions, including potential binding pockets.

ALLOX will use the funding to expand the platform, develop AI models that predict therapeutic opportunities from biophysical data and add staff to its drug discovery team. The company also plans to advance several research programs and establish collaborations with pharmaceutical and biotechnology companies. ALLOX appointed Morten Graugaard as independent chair of its board.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.